HCM
VYGR icon

Highline Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Highline Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-296,773
Closed -$8.08M – 39
2019
Q2 		$8.08M Sell
296,773
-292,024
-50% -$6.68M 0.59% 28
2019
Q1 		$11.3M Sell
588,797
-695,900
-54% -$9.06M 0.71% 29
2018
Q4 		$12.1M Buy
1,284,697
+282,827
+28% +$3.63M 0.81% 29
2018
Q3 		$19M Buy
1,001,870
+161,200
+19% +$3.09M 0.88% 26
2018
Q2 		$16.4M Buy
+840,670
New +$16.6M 0.55% 37

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highline Capital Management's VYGR Position: Q3 2019 in Review

Highline Capital Management sold out of Voyager Therapeutics (VYGR) in Q3 2019, closing a stake of 296,773 shares — an estimated $8.08M sold.

Highline Capital Management first reported a position in VYGR in Q2 2018 and held it in 5 quarters. The position peaked at $19M in Q3 2018. 131 funds tracked by Wall St. Rank hold VYGR as of Q3 2019.

  • Highline Capital Management reported no remaining Voyager Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Highline Capital Management sold 296,773 Voyager Therapeutics shares in Q3 2019, an estimated $8.08M.
  • Highline Capital Management first reported a position in Voyager Therapeutics in Q2 2018 and held it in 5 quarters.
  • Highline Capital Management's Voyager Therapeutics position peaked at $19M in Q3 2018.
  • 131 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2019.

Based on Highline Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.